Development and construct validation of the angioedema quality of life questionnaire

  • K. Weller
    Department of Dermatology and Allergy Allergie‐Centrum‐Charité Charité – Universitätsmedizin Berlin Berlin Germany
  • A. Groffik
    Department of Dermatology University Medical Center Mainz Mainz Germany
  • M. Magerl
    Department of Dermatology and Allergy Allergie‐Centrum‐Charité Charité – Universitätsmedizin Berlin Berlin Germany
  • N. Tohme
    Department of Dermatology and Allergy Allergie‐Centrum‐Charité Charité – Universitätsmedizin Berlin Berlin Germany
  • P. Martus
    Institute for Clinical Epidemiology and Applied Biometry Eberhard‐Karls University Tübingen Tübingen Germany
  • K. Krause
    Department of Dermatology and Allergy Allergie‐Centrum‐Charité Charité – Universitätsmedizin Berlin Berlin Germany
  • M. Metz
    Department of Dermatology and Allergy Allergie‐Centrum‐Charité Charité – Universitätsmedizin Berlin Berlin Germany
  • P. Staubach
    Department of Dermatology University Medical Center Mainz Mainz Germany
  • M. Maurer
    Department of Dermatology and Allergy Allergie‐Centrum‐Charité Charité – Universitätsmedizin Berlin Berlin Germany

書誌事項

公開日
2012-08-23
権利情報
  • http://onlinelibrary.wiley.com/termsAndConditions#vor
DOI
  • 10.1111/all.12007
公開者
Wiley

この論文をさがす

説明

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Recurrent angioedema is a frequent clinical problem characterized by unpredictably and rapidly occurring cutaneous and mucosal swellings. These swellings may be painful and/or disfiguring. Upper airway involvement can also lead to dyspnea and suffocation. Although the disease burden is high, there is currently no specific instrument to measure health‐related quality of life (QoL) impairment.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To develop and validate the first symptom‐specific tool to assess QoL impairment in recurrent angioedema patients, adhering to established methodological recommendations.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>During the development phase, 29 questions (items) were generated. Subsequently, item reduction was performed by means of impact analysis and factor analysis as well as by checking for content and face validity. As a result, 17 items were selected and included in the final instrument, the Angioedema QoL Questionnaire (<jats:styled-content style="fixed-case">AE</jats:styled-content>‐QoL). <jats:styled-content style="fixed-case">AE</jats:styled-content>‐QoL was then tested for its validity, reliability, and influence factors.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>One hundred and ten angioedema patients took part in the validation of <jats:styled-content style="fixed-case">AE</jats:styled-content>‐QoL. <jats:styled-content style="fixed-case">AE</jats:styled-content>‐QoL was found to have a four‐dimensional structure as well as a valid total score. All of its four domains (functioning, fatigue/mood, fears/shame, food) showed good levels of internal consistency with Cronbach's alpha > 0.8. Test–retesting revealed a good reliability of the instruments total score and domain scores. Gender as well as the patients' self‐rated disease activity was found to be predictors of the <jats:styled-content style="fixed-case">AE</jats:styled-content>‐QoL total score.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Angioedema Quality of Life Questionnaire is the first angioedema‐specific QoL questionnaire. It is a short, valid and reliable instrument that may serve as a valuable tool in future clinical studies and in routine patient care.</jats:p></jats:sec>

収録刊行物

  • Allergy

    Allergy 67 (10), 1289-1298, 2012-08-23

    Wiley

被引用文献 (9)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ